SMPD3 as a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Background and Aims: Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver cancer with high mortality rates. Sphingomyelin phosphodiesterase 3 (SMPD3) has recently been suggested to play an antitumor role in several cancers. This study is aimed at investigating the role of SMPD3 in HCC and its potential as a prognostic marker and therapeutic target.Methods: A retrospective cohort study of HCC patients was conducted using clinical data from our hospital. Survival analyses, including Kaplan-Meier and multivariate Cox regression, were performed to assess the impact of SMPD3 expression on survival. Further analyses were carried out using data from The Cancer Genome Atlas (TCGA) HCC cohort. In vitro and in vivo experiments were conducted to evaluate the effects of SMPD3 overexpression on HCC cell lines and tumor growth in mice.Results: High SMPD3 expression level was associated with improved survival in both our cohort and TCGA cohort. Multivariate Cox regression analysis confirmed high SMPD3 expression level as an independent predictor of better survival outcomes. In vitro and in vivo experiments demonstrated that SMPD3 overexpression significantly decreased HCC cell proliferation, migration, and invasion and inhibited tumor growth in a nude mouse model.Conclusions: SMPD3 plays a protective role in HCC by inhibiting tumor growth and progression. Its high expression is associated with better survival outcomes and may serve as a promising prognostic marker and potential therapeutic target in HCC. Further research into the molecular mechanisms of SMPD3's antitumor effects could lead to novel therapeutic strategies for HCC.